Trial Profile
Long Term Follow-up of Pegylated-Interferon Alpha-2b and Lamivudine Combination Therapy in Patients With Chronic HBV Infection
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Lamivudine (Primary) ; Peginterferon alfa-2b (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- 12 Nov 2020 Results of a pooled analysis of data pooled from 2 randomized trials (PARC and NCT00146705) the degree of on-treatment viral antigen decline among patients with pronounced HBV RNA decrease in relation to off-treatment sustained response and HBsAg loss published in the Alimentary Pharmacology and Therapeutics
- 13 Nov 2018 Results presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases
- 12 Nov 2008 New trial record.